Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL J LEONARD IV

Allopathic & Osteopathic Physicians Pediatrics

NPI
1801058243
CMS profile
500103
Location
HASTINGS, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$33.08

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $33.08 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Supernus Pharmaceuticals, Inc. $20.49 1
PFIZER INC. $12.59 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL J LEONARD IV

NPI 1801058243 · CMS profile ID 500103

Allopathic & Osteopathic Physicians / Pediatrics

HASTINGS, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801058243?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL J LEONARD IV, NPI 1801058243, CMS profile ID 500103. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801058243?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DANIEL J LEONARD IV, NPI 1801058243, CMS profile ID 500103. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801058243?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DANIEL J LEONARD IV, NPI 1801058243, CMS profile ID 500103, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1801058243?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $33.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Supernus Pharmaceuticals, Inc. $20.4911/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053276887 CMS
PFIZER INC. $12.0509/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049130133 CMS
PFIZER INC. $0.5409/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050416791 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $13.39 1
PY2023 $33.08 3
PY2024 $109.51 4
PY2025 $27.88 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $168,874.99 57
PY2024 Principal investigator $439,732.84 105
PY2023 Recipient $7,049.40 6
PY2023 Principal investigator $530,880.36 269
PY2022 Principal investigator $1,225,410.93 120
PY2021 Principal investigator $1,389,610.75 61
PY2020 Principal investigator $5,537.42 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

105 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $927.00 12/31/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
M21-862 Ph2 6 mo-2 yr old Functional Constipation Study (3051-201-001) No dispute reported 06/30/2026 1100766677
Principal investigator 1 ABBVIE INC. $927.00 12/31/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
M21-572 Ph3 Ped FC Trial 2-5 (LIN-MD-68) (3051-303-001) No dispute reported 06/30/2026 1100766679
Principal investigator 1 Merck Sharp & Dohme LLC $4,275.86 12/31/2024 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 1136406021
Principal investigator 1 Merck Sharp & Dohme LLC $42,709.72 12/31/2024 Non-covered Recipient Entity
Velocity Clinical Research, Grand Island
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1136436598
Principal investigator 1 Merck Sharp & Dohme LLC $741.60 12/31/2024 Non-covered Recipient Entity
Velocity Clinical Research, Grand Island
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1136438310
Principal investigator 1 ModernaTX, Inc. $566.86 12/23/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1147142886
Principal investigator 1 GlaxoSmithKline, LLC. $2,824.19 12/11/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PROSPECTIVE, MULTI-COUNTRY, MULTICENTRE COHORT STUDY TO ASSESS THE D No dispute reported 06/30/2026 1127529577
Principal investigator 1 SANOFI US SERVICES INC. $425.00 12/11/2024 Non-covered Recipient Entity
Meridian Clinical Research,llc
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 1128723305
Principal investigator 1 SANOFI US SERVICES INC. $425.00 12/11/2024 Non-covered Recipient Entity
Meridian Clinical Research,llc
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 1128723307
Principal investigator 1 Amgen Inc. $44.39 12/09/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
Ph3 Pediatric CM Study No dispute reported 06/30/2026 1096315067
Principal investigator 1 ABBVIE INC. $1,163.00 12/05/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100759555
Principal investigator 1 SANOFI US SERVICES INC. $577.15 12/02/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128728676
Principal investigator 1 Merck Sharp & Dohme LLC $85,598.80 11/22/2024 Non-covered Recipient Entity
Velocity Clinical Research, Grand Island
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1136436594
Principal investigator 1 SANOFI PASTEUR INC. $2,160.20 11/22/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1128703442
Principal investigator 1 SANOFI US SERVICES INC. $5,352.55 11/20/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128728678
Principal investigator 1 GlaxoSmithKline, LLC. $6,948.20 11/08/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127527034
Principal investigator 1 ModernaTX, Inc. $2,267.44 11/05/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1147142626
Principal investigator 1 PFIZER INC. $576.00 10/29/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130975314
Principal investigator 1 SANOFI PASTEUR INC. $9,531.90 10/28/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1128703464
Principal investigator 1 Amgen Inc. $3,010.00 10/25/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Phase P3 Pediatric Study EM No dispute reported 06/30/2026 1096315579
Principal investigator 1 ModernaTX, Inc. $1,300.00 10/25/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Double-Blind, Randomized, Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273.214SARS-CoV-2 Vaccine in Healthy Babies aged 0 to 6 months. No dispute reported 06/30/2026 1147135431
Principal investigator 1 ModernaTX, Inc. $625.00 10/25/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Double-Blind, Randomized, Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273.214SARS-CoV-2 Vaccine in Healthy Babies aged 0 to 6 months. No dispute reported 06/30/2026 1147135433
Principal investigator 1 SANOFI US SERVICES INC. $2,231.60 10/18/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128728680
Principal investigator 1 GlaxoSmithKline, LLC. $3,088.95 10/11/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3B, OPEN-LABEL, MULTI-COUNTRY, MULTI-CENTRE, LONG-TERM FOLLOW- No dispute reported 06/30/2026 1127527036
Principal investigator 1 SANOFI US SERVICES INC. $500.00 10/09/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128728682
Principal investigator 1 GlaxoSmithKline, LLC. $1,050.00 10/04/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1127529579
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 10/02/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128728684
Principal investigator 1 SANOFI US SERVICES INC. $5,000.00 10/01/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128728686
Principal investigator 1 GlaxoSmithKline, LLC. $3,362.93 09/20/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127527042
Principal investigator 1 ModernaTX, Inc. $566.86 09/18/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1147142064
Principal investigator 1 SANOFI US SERVICES INC. $2,412.20 09/18/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128728490
Principal investigator 1 GlaxoSmithKline, LLC. $80.06 09/06/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127527032
Principal investigator 1 GlaxoSmithKline, LLC. $17.45 09/06/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127527040
Principal investigator 1 GlaxoSmithKline, LLC. $384.95 09/06/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127529575
Principal investigator 1 GlaxoSmithKline, LLC. $2,159.34 09/05/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1127529587
Principal investigator 1 ABBVIE INC. $2,885.10 09/04/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100740126
Principal investigator 1 ModernaTX, Inc. $55.60 09/04/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1147135135
Principal investigator 1 SANOFI US SERVICES INC. $2,412.20 09/03/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128728488
Principal investigator 1 ModernaTX, Inc. $1,133.72 08/29/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1147141726
Principal investigator 1 GlaxoSmithKline, LLC. $2,528.72 08/22/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1127529565
Principal investigator 1 ModernaTX, Inc. $2,383.85 08/21/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1147134823
Principal investigator 1 GlaxoSmithKline, LLC. $3,103.67 08/14/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127527038
Principal investigator 1 ModernaTX, Inc. $3,000.00 08/14/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1147141720
Principal investigator 1 ModernaTX, Inc. $1,100.00 08/09/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147134563
Principal investigator 1 ModernaTX, Inc. $3,000.00 08/09/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147134565
Principal investigator 1 GlaxoSmithKline, LLC. $2,408.40 07/17/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127527044
Principal investigator 1 ModernaTX, Inc. $1,250.00 07/17/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1147134095
Principal investigator 1 ABBVIE INC. $1,176.60 07/05/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100727436
Principal investigator 1 ABBVIE INC. $226.00 07/03/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100725850
Principal investigator 1 Merck Sharp & Dohme LLC $6,000.00 07/03/2024 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 1136406017
Principal investigator 1 ModernaTX, Inc. $2,745.06 06/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1147141592
Principal investigator 1 ModernaTX, Inc. $16,137.03 06/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1147141618
Principal investigator 1 ModernaTX, Inc. $106.20 06/25/2024 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1147183227
Principal investigator 1 GlaxoSmithKline, LLC. $1,382.10 06/21/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127529573
Principal investigator 1 ModernaTX, Inc. $36.43 06/14/2024 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1147183225
Principal investigator 1 ABBVIE INC. $2,505.00 06/06/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100722634
Principal investigator 1 Genentech, Inc. $153.00 05/21/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A phase IIIB surveillance study of susceptibility to baloxavir marboxil No dispute reported 06/30/2026 1133472794
Principal investigator 1 Genentech, Inc. $876.00 05/21/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A phase IIIB surveillance study of susceptibility to baloxavir marboxil No dispute reported 06/30/2026 1133472842
Principal investigator 1 ModernaTX, Inc. $2,999.70 05/17/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1147141502
Principal investigator 1 SANOFI US SERVICES INC. $14,500.00 05/17/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128728466
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 05/17/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128728468
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 05/17/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128728470
Principal investigator 1 SANOFI US SERVICES INC. $3,500.00 05/17/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128728472
Principal investigator 1 Genentech, Inc. $1,023.00 05/16/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A phase IIIB surveillance study of susceptibility to baloxavir marboxil No dispute reported 06/30/2026 1133472799
Principal investigator 1 Genentech, Inc. $3,687.00 05/16/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A phase IIIB surveillance study of susceptibility to baloxavir marboxil No dispute reported 06/30/2026 1133472802
Principal investigator 1 GlaxoSmithKline, LLC. $345.17 05/15/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127527030
Principal investigator 1 ABBVIE INC. $6,186.60 05/09/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100717288
Principal investigator 1 Amgen Inc. $260.52 05/08/2024 Non-covered Recipient Entity
MERIDIAN CLIN. RESEARCH LLC
Ph3 Pediatric CM Study No dispute reported 06/30/2026 1096315069
Principal investigator 1 ModernaTX, Inc. $763.82 05/03/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147133635
Principal investigator 1 ModernaTX, Inc. $175.49 04/26/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1147132983
Principal investigator 1 ModernaTX, Inc. $1,773.90 04/24/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147133361
Principal investigator 1 Amgen Inc. $11,377.00 04/20/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
Phase P3 Pediatric Study EM No dispute reported 06/30/2026 1096315503
Principal investigator 1 GlaxoSmithKline, LLC. $1,300.00 04/18/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1127529583
Principal investigator 1 PFIZER INC. $1,393.65 04/18/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131057735
Principal investigator 1 SANOFI PASTEUR INC. $21,500.00 04/18/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) No dispute reported 06/30/2026 1128703052
Principal investigator 1 GlaxoSmithKline, LLC. $2,711.95 04/11/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1127529585
Principal investigator 1 Amgen Inc. $163.36 04/08/2024 Non-covered Recipient Entity
MERIDIAN CLIN. RESEARCH LLC
Phase P3 Pediatric Study EM No dispute reported 06/30/2026 1096315505
Principal investigator 1 ABBVIE INC. $2,931.00 04/04/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation No dispute reported 06/30/2026 1100711298
Principal investigator 1 ModernaTX, Inc. $6,817.95 04/01/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1147133011
Principal investigator 1 GlaxoSmithKline, LLC. $9,081.93 03/27/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1127529581
Principal investigator 1 ModernaTX, Inc. $4,795.00 03/27/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1147141128
Principal investigator 1 PFIZER INC. $916.75 03/21/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131049541
Principal investigator 1 ABBVIE INC. $4,000.00 03/14/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide No dispute reported 06/30/2026 1100708511
Principal investigator 1 GlaxoSmithKline, LLC. $341.70 03/13/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127529571
Principal investigator 1 Genentech, Inc. $50.60 03/11/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A phase IIIB surveillance study of susceptibility to baloxavir marboxil No dispute reported 06/30/2026 1133472767
Principal investigator 1 ModernaTX, Inc. $843.75 03/11/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1147141126
Principal investigator 1 ModernaTX, Inc. $1,500.00 03/08/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Healthy Younger Adults Aged 18 to 49 Years, Women of Child-Bearing Potential Aged 18 to 40 Years, Healthy Older Adults Aged 65 to 79 Years, and RSV-Seropositive Children Aged 12 to 59 Months No dispute reported 06/30/2026 1147132549
Principal investigator 1 ABBVIE INC. $6,452.55 03/07/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 1100707178
Principal investigator 1 ModernaTX, Inc. $14,250.62 03/06/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1147141124
Principal investigator 1 ModernaTX, Inc. $2,668.90 02/28/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1147140842
Principal investigator 1 Genentech, Inc. $7,374.00 02/23/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A phase IIIB surveillance study of susceptibility to baloxavir marboxil No dispute reported 06/30/2026 1133472755
Principal investigator 1 Genentech, Inc. $227.00 02/23/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A phase IIIB surveillance study of susceptibility to baloxavir marboxil No dispute reported 06/30/2026 1133472763
Principal investigator 1 PFIZER INC. $916.75 02/15/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131050354
Principal investigator 1 GlaxoSmithKline, LLC. $689.89 02/09/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127529569
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 02/08/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1127529589
Principal investigator 1 ABBVIE INC. $1,192.05 02/02/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 1100702618
Principal investigator 1 ModernaTX, Inc. $1,067.56 02/01/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1147140836
Principal investigator 1 Amgen Inc. $19,487.08 01/25/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Phase P3 Pediatric Study EM No dispute reported 06/30/2026 1096315581
Principal investigator 1 ModernaTX, Inc. $1,601.34 01/25/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1147140518
Principal investigator 1 ModernaTX, Inc. $1,136.03 01/25/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1147140544
Principal investigator 1 PFIZER INC. $3,750.60 01/18/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131062219
Principal investigator 1 GlaxoSmithKline, LLC. $339.02 01/12/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1127529567
Principal investigator 1 ABBVIE INC. $14,000.00 01/10/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide No dispute reported 06/30/2026 1100699831
Principal investigator 1 Amgen Inc. $657.38 01/09/2024 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
Ph3 Pediatric CM Study No dispute reported 06/30/2026 1096315065
Principal investigator 1 ABBVIE INC. $2,296.35 01/04/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 1100698969